deltatrials
Completed PHASE2 NCT00003464

Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme

Phase II Treatment of Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme With Temodal

Sponsor: Duke University

Conditions Brain and Central Nervous System Tumors
Interventions radiation therapy temozolomide
Updated 5 times since 2017 Last updated: Jun 19, 2013 Started: Sep 30, 1997 Completion: Aug 31, 2003

Listed as NCT00003464, this PHASE2 trial focuses on Brain and Central Nervous System Tumors and remains completed. Sponsored by Duke University, it has been updated 5 times since 1997, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Sep 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Duke University
  • National Cancer Institute (NCI)
Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Durham, United States